Join to View Full Profile
800 W Magnolia AveFort Worth, TX 76104
Phone+1 817-759-7000
Dr. Xiong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1995 - 1998
Shanghai Medical UniversityClass of 1984
Certifications & Licensure
TX State Medical License 1999 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
Clinical Trials
- Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2003 Dec 01
- CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2003 Dec 01
- S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer Start of enrollment: 2006 Nov 01
Publications & Presentations
PubMed
- 50 citationsPhase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)Herbert Hurwitz, Benjamin R. Tan, James A. Reeves, Henry Xiong, Brad Somer
The Oncologist. 2019-07-01 - 1 citationsTwo phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.Kamalesh Kumar Sankhala, Chris H. Takimoto, Alain C. Mita, Henry Xiong, Jordi Rodon
Investigational New Drugs. 2019-02-01 - 1 citationsPhase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancerAmir Mehrvarz Sarshekeh, Henry Q. Xiong, Kenzo Iizuka, Howard S. Hochster, Scott Kopetz
Investigational New Drugs. 2018-06-13
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
